Bluebird bio, Inc.
BLUE
Peringkat dalam Saham
#15677
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Harga Saham
$4.97
Terakhir disinkronkan: 2025-06-02
Kapitalisasi Pasar
$318.62M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-38.03%
Negara
US
Perdagangan Bluebird bio, Inc. (BLUE)
Kategori
Healthcare
Kapitalisasi pasar dari Bluebird bio, Inc.(BLUE)
Kapitalisasi Pasar: $318.62M
Per October 2026, Bluebird bio, Inc. memiliki kapitalisasi pasar sebesar $318.62M. Ini menjadikan Bluebird bio, Inc. sebagai perusahaan 15677th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Bluebird bio, Inc. dari 2018 hingga 2026
BLUE dibandingkan dengan 5 teratas stocks paling populer
